Showing 831 - 840 of 856 for "Pharmaceutical" with applied filters
Filters:
09 March 2020 by Chris Adams
Read the latest IP practitioner hires, departures and other IP-related news concerning firms in Canada, Latin America and the US
02 January 2020 by Kingsley Egbuonu
The two European patent attorneys strengthen the firm's pharmaceutical and telecoms patent practice
11 November 2019 by Jonathan Lahura and Adriana Barrera
The Peruvian Patent Office has published the new guidelines for obtaining a compulsory license
17 October 2019 by Kingsley Egbuonu
To celebrate the 10-year anniversary of the UK Supreme Court, Managing IP featured some of the decisions of the court and the pending appeals involving firms such as Allen & Overy, Bristows, EIP Legal, Herbert Smith Freehills, Osborne Clarke and Powell Gilbert
02 October 2019 by Indran Shanmuganathan, Michelle Loi Choi Yoke, and Yap Khai Jian
Indran Shanmuganathan, Michelle Loi Choi Yoke, and Yap Khai Jian of Shearn Delamore & Co provide an in-depth analysis of the Federal Court’s decision in Merck Sharp & Dohme & Anor v Hovid Berhad, a patentee-friendly judgment which overturned a previous ruling on the assessment of dependent and independent claims
17 August 2019 by Chris Adams and Kingsley Egbuonu
The firm hired four IP litigators, two of whom are ranked as patent stars, from a rival
31 July 2019 by Saya Choudhary Kapur and Vivek Ranjan
Saya Choudhary Kapur and Vivek Ranjan of Singh & Singh Law Firm examine the regulations surrounding medical devices in India and compare the law around patenting methods of treatment with that in the US and Europe
30 July 2019 by Kingsley Egbuonu
Four law firms were involved in the multi-billion dollar merger of Mylan and Upjohn, Pfizer’s off-patent branded and generics business
01 July 2019 by Kingsley Egbuonu
Some IP firms in Asia-Pacific and Europe announced promotions and appointments today
05 June 2019 by Alexander Robinson and Stephen Garner
Alexander Robinson and Stephen Garner of Mathys & Squire explore some of the regulatory issues in the life sciences and pharmaceutical sectors that are likely to be affected by Brexit
